ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.25 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $250.87M, closed the recent trade at $1.50 per share which meant it lost -$0.08 on the day or -5.38% during that session. The ATAI stock price is -90.0% off its 52-week high price of $2.85 and 31.33% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.22 million shares traded. The 3-month trading volume is 1.74 million shares.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Sporting -5.38% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ATAI stock price touched $1.50 or saw a rise of 8.26%. Year-to-date, ATAI Life Sciences N.V shares have moved 12.41%, while the 5-day performance has seen it change 2.40%. Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed 24.58%. Short interest in the company has seen 10.74 million shares shorted with days to cover at 8.36.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 75.0% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -300.0% off the targeted high while a plunge would see the stock gain -300.0% from the levels at last check today.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Figures show that ATAI Life Sciences N.V shares have underperformed across the wider relevant industry. The company’s shares have lost -5.38% over the past 6 months, with this year growth rate of -208.00%, compared to 13.20% for the industry. Revenue growth from the last financial year stood is estimated to be 159.03%.
6 analysts offering their estimates for the company have set an average revenue estimate of 250k for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 44.19% over the past 5 years.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Insiders own 10.00% of the company shares, while shares held by institutions stand at 26.66% with a share float percentage of 29.62%. Investors are also buoyed by the number of investors in a company, with ATAI Life Sciences N.V having a total of 105.0 institutions that hold shares in the company. The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7388% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.7111% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port. As of Oct 31, 2024 , the former fund manager holds about 0.47% shares in the company for having 794.76 shares of worth $1.16 million while later fund manager owns 511.99 shares of worth $0.75 million as of Sep 30, 2024 , which makes it owner of about 0.31% of company’s outstanding stock.
